COMPANY

Curis

Keywords: oncology cancer Lymphoma Head and Neck Cancer Relapsed Hematologic Malignancy Refractory Hematologic Malignancy Relapsed Primary Central Nervous System Lymphoma Refractory Primary Central Nervous System Lymphoma Chronic Lymphocytic Leukemia B-cell Malignancies Acute Myelogenous Leukemia Myelodysplastic Syndrome Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations Relapsed Lymphoma Refractory Lymphoma Relapsed and/or Refractory Lymphoma Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Double-hit Lymphoma Triple-hit Lymphoma Double-expressor Lymphoma High-grade B-cell Lymphoma Triple-Negative Breast Cancer High-grade Serous Ovarian Cancer NUT Midline Carcinoma Liver Cancer Breast Cancer Gastric Cancer Non-Small Cell Lung Cancer CUDC-101 CUDC-907 CI-8993 CA-170 CUDC-427

Profile checked Oct 10, 2026

$39.3MRaised (2 yrs)13Trials (company is sponsor)

Timeline

Apr 23, 2026 Trial start Phase 2: A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies source ↗
Jan 8, 2026 Raise Private placement: $20.2M (initial closing, as published); deal value up to $80.8M (not counted as received), announced Jan 8, 2026. Source: SEC filing. source ↗
Jul 2, 2025 Raise Private placement: $7M (total, as published), announced Jul 2, 2025. Source: SEC filing. source ↗
Oct 29, 2024 Raise Private placement: $12.1M (total, as published), announced Oct 29, 2024. Source: SEC filing. source ↗
Sep 22, 2020 Trial start 1: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies source ↗
Jul 6, 2020 Trial start Phase 1/Phase 2: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) source ↗
Dec 28, 2017 Trial start Phase 1/Phase 2: CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) source ↗
2016-07 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations source ↗
2016-05 Trial start Phase 1: A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas source ↗
2014-11 Trial start Phase 1: Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors source ↗
2013-07 Trial start I: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma source ↗
2012-12 Trial start Phase 1: Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma source ↗
2012-09 Trial start I: Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients source ↗
2011-11 Trial start I: Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer source ↗
2010-07 Trial start I: A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung C source ↗
2008-08 Trial start I: A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

2027-07 (ESTIMATED) · Phase 1/Phase 2 · CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) · NCT03328078
2027-11 (ESTIMATED) · Phase 2 · A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies · NCT07271667

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $39.3M. Last 2 years.

Jan 8, 2026 Private placement: $20.2M (initial closing, as published); deal value up to $80.8M (not counted as received), announced Jan 8, 2026. Source: SEC filing. source ↗
Jul 2, 2025 Private placement: $7M (total, as published), announced Jul 2, 2025. Source: SEC filing. source ↗
Oct 29, 2024 Private placement: $12.1M (total, as published), announced Oct 29, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT03328078	CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)	Phase 1/Phase 2	Recruiting	Dec 28, 2017	2027-07 (estimated)
NCT07271667	A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies	Phase 2	Recruiting	Apr 23, 2026	2027-11 (estimated)
NCT04278768	Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Phase 1/Phase 2	Suspended	Jul 6, 2020	Apr 1, 2026 (estimated)
NCT04475523	Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies	1	Completed	Sep 22, 2020	May 19, 2023 (actual)
NCT02674750	Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations	Phase 2	Completed	2016-07	May 28, 2019 (actual)
NCT01742988	Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma	Phase 1	Completed	2012-12	Oct 9, 2020 (actual)
NCT02812875	A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas	Phase 1	Completed	2016-05	May 7, 2020 (actual)
NCT02307240	Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors	Phase 1	Completed	2014-11	May 31, 2019 (actual)
NCT00728793	A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors	I	Completed	2008-08	2010-04 (actual)
NCT01384799	Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer	I	Completed	2011-11	2013-09 (actual)
NCT01702285	Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients	I	Terminated	2012-09	2012-12 (actual)
NCT01908413	Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma	I	Terminated	2013-07	2015-03 (actual)
NCT01171924	A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors	I	Completed	2010-07	2011-10 (actual)